PLX
$2.79
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
Intraday
Recent News
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen for pegunigalsidase alfa for adults with Fabry disease who are stable on enzyme replacement therapy (ERT), triggering a $25 million regulatory milestone payment from...
3 Promising Penny Stocks With Market Caps Up To $400M
The U.S. stock market kicked off February with a strong performance, as major indexes like the Dow Jones and S&P 500 posted significant gains. Amidst this backdrop of optimism, investors are exploring various opportunities across different market segments. While penny stocks might seem like a throwback to earlier trading days, they continue to offer intriguing possibilities for those interested in smaller or emerging companies with potential growth prospects.
Baozun And 2 Other Promising Penny Stocks
As the U.S. stock market experiences a surge, with major indexes like the S&P 500 reaching new all-time highs, investors are increasingly looking for opportunities beyond traditional large-cap stocks. Despite its somewhat outdated connotation, the term "penny stock" continues to highlight investment potential in smaller or newer companies that may offer significant returns when backed by strong financials. In this article, we explore three penny stocks that demonstrate balance sheet...
Protalix BioTherapeutics Inc (PLX) Q3 2025 Earnings Call Highlights: Navigating Revenue ...
Despite a slight dip in quarterly revenue, Protalix BioTherapeutics Inc (PLX) remains focused on growth with promising clinical advancements and a strong cash position.
Protalix: Q3 Earnings Snapshot
HACKENSACK, N.J. (AP) — Protalix BioTherapeutics Inc. PLX) on Thursday reported earnings of $2.4 million in its third quarter. On a per-share basis, the Hackensack, New Jersey-based company said it had net income of 3 cents.